New PKU drug study aims to unlock a more normal diet and life
NCT ID NCT04404530
Summary
This study is observing adults with PKU who are starting a new, FDA-approved drug called Palynziq. Researchers want to see how this treatment affects what people can eat, their brain function, nutritional status, and overall quality of life over three to five years. The goal is to understand the full impact of this new therapy beyond just lowering blood Phe levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital Georgia Clinical Research Center
RECRUITINGAtlanta, Georgia, 30322, United States
-
The Emory Clinic
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.